Flamingo Therapeutics Presents at ASH 2024
Flamingo Therapeutics, a trailblazer in RNA-targeted therapies for oncology, has proudly announced the selection of an abstract for poster presentation at an upcoming significant medical meeting. This event is the 66th Annual Meeting and Exposition, widely recognized in the field of hematology, where important research findings will be shared.
Details of the Presentation
The abstract pertains to a Phase 1 investigator-initiated study, focusing on the innovative danvatirsen monotherapy, followed by its combination with venetoclax. This study is crucial for patients suffering from relapsed or refractory acute myeloid leukemia (AML) and those with intermediate to high-risk myelodysplastic syndromes (MDS). The registered study, under the ID NCT05986240, is being conducted at renowned healthcare institutions.
Poster Presentation Highlights
The poster presentation includes vital components such as:
- Title: A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed by Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
- Session Date: Scheduled for a Monday slot on December 9, 2024
- Presenting Author: Dr. Aditi Shastri
Innovative Research in Oncology
Flamingo Therapeutics has carved out a vital niche focusing on undruggable transcription factors and long non-coding RNAs. Their commitment to advancing cancer therapies is further solidified through partnerships with established biotechnology leaders such as Ionis Pharmaceuticals. Various well-regarded investors also support their efforts, ensuring continued progress in their research and development initiatives.
Current Clinical Trials
In addition to the aforementioned study, Flamingo Therapeutics has initiated a Phase II clinical trial titled 'PEMDA-HN.' This trial is evaluating the efficacy of danvatirsen combined with pembrolizumab for patients with head and neck squamous cell carcinoma (HNSCC). Moreover, they are pursuing a Phase I trial, which is pivotal in exploring the potential of danvatirsen, both as a standalone therapy and in conjunction with venetoclax, in treating patients with AML/MDS.
Commitment to Life-Saving Therapies
Flamingo Therapeutics is unwavering in its mission to transform the landscape of cancer treatment with innovative RNA-targeted therapies. The implications of their research could be transformational for many individuals battling these diseases. Their ongoing clinical trials are a testament to their dedication towards finding effective treatment modalities.
About Flamingo Therapeutics
Flamingo Therapeutics is at the forefront of biotechnology research, focusing on the development of RNA-based therapies for hematological malignancies. With a commitment to pushing boundaries in oncology, they ensure that their therapies address critical unmet medical needs in the oncology space.
Frequently Asked Questions
What is the main focus of Flamingo Therapeutics?
Flamingo Therapeutics specializes in RNA-targeted therapies aimed at treating various types of cancers, particularly focusing on undruggable targets.
When will the poster presentation take place?
The poster presentation is scheduled for December 9, 2024, during the ASH Annual Meeting.
What conditions are being studied in the clinical trials?
The clinical trials focus on relapsed/refractory AML and intermediate/high-risk MDS, investigating innovative combinations and monotherapies using danvatirsen.
Who is the presenting author of the research?
Dr. Aditi Shastri is the presenting author for the specified poster presentation at the ASH 2024 meeting.
How does Flamingo connect with the community?
Flamingo Therapeutics engages with the wider community through platforms like LinkedIn, sharing updates on their advancements and fostering connections in the industry.
